Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GKB OphthalmicsNSE:GKB 44 6-1 Month Momentum % is N/A% as of Aug. 26, 2026. GuruFocus rates NSE:GKB with a GF Score™ of 44/100 and a GF Value™ of ₹126.38 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 843 Medical Devices & Instruments companies, GKB Ophthalmics ranks better than 57.53% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-26), GKB Ophthalmics's 6-1 Month Momentum % is N/A%.
The industry rank for GKB Ophthalmics's 6-1 Month Momentum % or its related term are showing as below:
NSE:GKB's 6-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -14.79 * Ranked among companies with meaningful 6-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
GKB Ophthalmics 6-1 Month Momentum % Related Terms
NSE:GKB vs ISRG, BDX, MDLN: 6-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, GKB Ophthalmics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GKB Ophthalmics 6-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GKB Ophthalmics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where GKB Ophthalmics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKB Ophthalmics (NSE:GKB) has a 6-1 Month Momentum % of N/A% as of Aug. 26, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on GKB Ophthalmics and its competitors. According to the industry distribution chart, GKB Ophthalmics ranks #358 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 42.5%.
Is GKB Ophthalmics' 6-1 Month Momentum % too high?
GKB Ophthalmics' current 6-1 Month Momentum % is N/A%. Based on the distribution chart, GKB Ophthalmics ranks #358 out of 843 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, GKB Ophthalmics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GKB Ophthalmics' 6-1 Month Momentum % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, GKB Ophthalmics ranks #358 out of 843 companies for 6-1 Month Momentum %. This puts GKB Ophthalmics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Medical Devices & Instruments company?
A good 6-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on GKB Ophthalmics and its competitors. GKB Ophthalmics's current 6-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GKB Ophthalmics stock overvalued right now?
Based on GuruFocus' analysis, GKB Ophthalmics (NSE:GKB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.38, compared to a current price of ₹63.00 — trading 50.2% below its estimated fair value. The current 6-1 Month Momentum % is N/A%. GKB Ophthalmics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For GKB Ophthalmics (NSE:GKB), the current 6-1 Month Momentum % is N/A% as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GKB Ophthalmics (NSE:GKB) Overvalued in 2026?
Based on GuruFocus' analysis, GKB Ophthalmics stock appears to be undervalued.
The current stock price of ₹63.00 is trading 50.2% below its estimated GF Value™ of ₹126.38.
GuruFocus considers GKB Ophthalmics to be Significantly Undervalued.
Key valuation signals for NSE:GKB:
6-1 Month Momentum %: N/A%
GF Value™: ₹126.38 vs. price of ₹63.00 (50.2% below fair value)
No single metric tells the full story. See the NSE:GKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GKB Ophthalmics Ltd is an India-based company engaged in manufacturing and exporting ophthalmics lenses. It manufactures glass and plastic lenses both semi-finished and finished forms. The other products of the company include Organic lenses, Glass moulds, and Bifocal moulds. The company sells its products in India and also exports globally. Geographically, the majority of its revenue is generated from outside of India.
44GF Score
Get the complete analysis for NSE:GKB
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKB has been successfully added to your 
